The second annual Lupus Insight Prize, presented in a collaboration among the Alliance for Lupus Research (ALR), the Lupus Foundation of America (LFA) , and the Lupus Research Institute (LRI) will be awarded by the three organizations to recognize and honor an outstanding investigator with a documented record of creativity, innovation, and productivity. The researcher will also be someone who has made a novel insight in an area of research that is applicable to the pathogenesis or treatment of lupus and is judged to have a high likelihood of generating further advances by applying that insight to lupus.
The 2014 Lupus Insight Prize recipient will be awarded $200,000 to be used for research dedicated to advancing understanding of the genetic, environmental, molecular, immunologic or cellular aspects of lupus and/or its treatment. The Prize must be utilized within three years from the date it is awarded.
Nominations will be reviewed by members of an independent Selection Committee comprised of representatives of the three funding lupus organizations. The Committee will review nominations and award the Prize based on a variety of criteria, including academic achievements, creativity, insight, and potential for future advances that will impact people with lupus.
The full application must be submitted by the Nominator and the Candidate electronically by February 20, 2014 at 5 p.m. ET, The Prize recipient will be announced and honored publicly at the FOCIS Meeting on June 25, 2014 in a ceremony hosted by the three organizations.
Please RSVP to Diomaris Gonzalez at email@example.com.
The Lupus Insight Prize will be awarded on June 25, 2014 during the 2014 FOCIS Meeting.
You do not need to be registered for the FOCIS Meeting in order to attend the
2014 Lupus Insight Prize Ceremony and Reception.
The institution of the Prize recipient will receive $200,000 to be used at the discretion of the recipient scientist with the expectation that those funds will be applied to research dedicated to advancing understanding of the genetic, environmental, molecular, immunologic or cellular aspects of lupus and/or its treatment. The Prize can be transferred to another institution (within the U.S.) in the event
Nominations for the Lupus Insight Prize should represent collaboration between the Nominator and Candidate. Nominations of basic, clinical, and translational scientists will be considered. Candidates can be investigators of any age or rank affiliated with an academic, biomedical, research, or government institution in the United States. Nominations will not be accepted for investigators working in the biotechnology or pharmaceutical industries. Additionally, Candidates may not already possess a grant award to pursue the aims described in the application for the Prize. Co-investigators or teams of investigators are not eligible for the Lupus Insight Prize.
Nominators and Candidates should work together to prepare each Candidate's Letter of Nomination for The Lupus Insight Prize. Nominations of basic, clinical, and translational scientists will be considered. The Nominator should submit a two-page Letter of Nomination, describing the worthiness, expertise and achievements of the Candidate and specifically focus on the unique insight generated by the Candidate that might have an impact on advancing the future of lupus research. The letter of Nomination should clearly state the insight for which the candidate is being nominated.
- a description of the novel hypothesis, innovative concept, or unusually creative experimental approach that will be applied to lupus by the Candidate
- anticipated goal of the proposed project
- potential impact of the proposed research on the field as a whole, as well as its potential to galvanize, change, and/or revolutionize lupus research or treatment
The Research Narrative should not be considered as a grant application, but should describe the applicant's unique insight and its potential to move lupus research forward. The Research Narrative should be a stand-alone document and cannot include any web links to additional materials. Appendices will not be accepted.
In addition to the Research Narrative, the Candidate should also submit a complete CV. Two blind letters in support of the Candidate (from people other than the Nominator) must also be solicited by the Candidate, and each must be submitted directly via proposalCENTRAL by the individual writing each letter. The application will not be considered complete without the two blind letters in support of the Candidate.
Each full application must be received electronically by February 20, 2014 at 5 p.m. ET via Altumís proposalCENTRAL online system at https://proposalcentral.altum.com/. Hard copies will not be accepted under any circumstances.
Dr. Bruce Richardson Selected as the Second Recipient of the
Lupus Insight Prize
CHICAGO, IL (June 9, 2014) – Bruce Richardson, M.D., Ph.D., of The University of Michigan, has been selected as the second recipient of the Lupus Insight Prize. The award provides $200,000 for use in innovative research on lupus, an unpredictable and sometimes fatal autoimmune disease that affects an estimated 1.5 million Americans.
The Prize is a collaborative initiative among the Alliance for Lupus Research (ALR), the Lupus Foundation of America (LFA), and the Lupus Research Institute (LRI) to recognize and honor the achievements of an outstanding investigator in the field, and whose research efforts have a high likelihood of generating further advances in understanding of the causes, biology, treatments, or cure of lupus.
Dr. Richardson will receive the Prize on June 25 during a formal ceremony at FOCIS 2014, the Annual Meeting of the Federation of Clinical Immunology Societies in Chicago, where scientists will present their findings on lupus and other diseases affecting the immune system.
Many researchers believe that lupus flares are triggered by environmental agents such as ultraviolet light, infections, silica exposure and cigarette smoking as well as certain drugs. How these agents cause lupus flares though, has been unclear. Dr. Richardson discovered that some lupus-causing drugs alter gene expression in normal "helper" lymphocytes, converting them into autoreactive "killer" lymphocytes that attack other cells and cause lupus in mice. He also found the same changes in gene expression in lymphocytes from patients with active lupus, and that many of the environmental agents implicated in lupus, as well as diet, contribute to the changes by altering gene expression. With the award funds, Dr. Richardson will identify the genes affected by these environmental agents, and determine how environmental agents and diet cause these changes in lymphocytes.
"I have dedicated my entire career to solving the problem of lupus. This award will enable me to take one of the most creative and innovative steps in my journey to have an impact on understanding and treating this difficult disease," said Dr. Richardson in response to the award announcement. "I am tremendously honored to receive this award that has been initiated cooperatively by these three outstanding lupus advocacy and research organizations."
Dr. Richardson was chosen to receive the Lupus Insight Prize by an independent review committee composed of leading lupus scientific leaders from across the country and representatives of the three lupus organizations. The selection committee based the award on a variety of criteria, including academic achievements, creativity, insight, and potential for future advances that will improve the lives of people with lupus.
"I am thrilled to see the culmination of the collaborative efforts of the Alliance for Lupus Research, the Lupus Foundation of America, and the Lupus Research Institute on the development of this important prize with the selection of Bruce Richardson as the second recipient," said Mary Crow, M.D., Chair of the Scientific Advisory Board of the Alliance for Lupus Research. "As we recognize Dr. Richardson's important insights into the impact of environment on the genome and immune function to characterize the immune system alterations that contribute to lupus, we can look forward to future advances that improve the lives of lupus patients," she said.
Gary Gilkeson, M.D., Chair of the Lupus Foundation of America's Medical-Scientific Advisory Council, noted the important contribution of Dr. Richardson's work in expanding scientific understanding of lupus. "The origins of lupus are not well defined. Dr. Richardson's work has provided a strong foundation from which further advances in the understanding and treatment of this very complex disease are being made."
Lupus Research Institute's Scientific Advisory Board member Peter Lipsky, M.D. commented, "The Lupus Insight Prize recognizes the novel insight of Dr. Richardson, who made the unexpected discovery that lupus-causing drugs change gene expression in immune cells. This insight provides a unique opportunity to develop new approaches for potential novel therapies for human lupus."
Additional information about the Lupus Insight Prize and Dr. Richardson's work in lupus are available online at www.lupusinsightprize.org.
Lupus is a chronic autoimmune disease that causes inflammation and tissue damage to any organ system in the body. The health effects of lupus include heart attacks, strokes, seizures, organ failure, and possible death. An estimated 1.5 million Americans and at least five million people worldwide have lupus.
About the Funding Organizations
For more information about the Alliance for Lupus Research, visit www.lupusresearch.org.
For more information about the Lupus Foundation of America, visit www.lupus.org.
For more information about the Lupus Research Institute, visit www.lupusresearchinstitute.org.
FOCIS exists to improve human health through immunology by fostering interdisciplinary approaches to understand and treat immune-based diseases. FOCIS 2014 is the 14th Annual Meeting of the Federation of Clinical Immunology Societies in Boston, where scientists will present their findings on lupus and other diseases affecting the immune system. Thirty different specialties will be represented and over three hundred scientific papers will be presented.
Courtney Love, Alliance for Lupus Research, firstname.lastname@example.org, 212-218-2869
Duane Peters, Lupus Foundation of America, email@example.com, 202-349-1145
Margy Meislin, Lupus Research Institute, firstname.lastname@example.org, 212-685-4118 x 34
Sarah Martis, Federation of Clinical Immunology Societies, email@example.com, 414-359-1670 x1103
Source: Alliance for Lupus Research
Dr. Mark J. Shlomchik Receives Lupus Insight Prize Recognizing Outstanding Contribution in Lupus Research
JUNE 27, 2013
WASHINGTON, DC -- Mark J. Shlomchik, M.D., Ph.D., the incoming Chair of Immunology at the University of Pittsburgh, was honored Thursday as the first recipient of the Lupus Insight Prize, the first-of-a-kind award for use in innovative research on lupus, an unpredictable and sometimes fatal autoimmune disease that affects an estimated 1.5 million Americans. Dr. Shlomchik received the Prize during a formal ceremony at FOCIS 2013, the 13th Annual Meeting of the Federation of Clinical Immunology Societies in Boston.
The Prize is a collaborative initiative among the Alliance for Lupus Research, the Lupus Foundation of America, and the Lupus Research Institute to recognize and honor the achievements of an outstanding investigator in the field whose research efforts have a high likelihood of generating further advances in understanding the causes, biology, treatments, or cure of lupus.
"I would like to thank the three sponsoring organizations for bestowing this honor upon me," said Dr. Shlomchik. "Lupus is a very complex disease for which I have devoted much of my career. This award will enable me to further my research and make important contributions to understanding and treating this difficult disease."
With the award funds, Dr. Shlomchik will investigate the connection between the death of neutrophils, the body's most abundant white blood cells, and lupus. Many researchers believe lupus is the result of an abnormal immune response to dying cells. To fight infections, neutrophils use a molecule called NADPH oxidase. It was thought that this molecule may cause these neutrophils to die in a way that promotes an autoimmune response. However, to the surprise of most lupus researchers, Dr. Shlomchik discovered that lupus-prone mice that are missing this gene, have markedly worse diseaseóthe opposite of the original theory.
Dr. Shlomchik will create new animal models of lupus that produce neutrophils lacking NADPH oxidase to test how this molecule prevents animals from developing severe lupus. Because NADPH oxidase is turned on by infections, the work could help researchers understand the role infections might play in triggering lupus.
"We are pleased to collaborate with the other organizations to find better ways to manage lupus and, ultimately, to find a cure," said Ken Farber, President of the Alliance for Lupus Research. "By bringing together leaders in their fields, and those with a common focus, we have the opportunity to positively impact the well-being of the 1.5 million Americans with lupus."
"Dr. Shlomchik's work has provided insight into the underlying causes of lupus and has identified pathways for further research," said Sandra Raymond, President and CEO of the Lupus Foundation of America. "Continued support of these research efforts on lupus holds promise of generating further advances in the diagnosis and treatment of this devastating disease."
Lupus Research Institute President and CEO Margaret Dowd commented, "The Lupus Insight Prize recognizes Dr. Shlomchik's outstanding contributions to the field and supports his ability to continue his innovative work. Judging by the exceptional quality of Dr. Shlomchik's work, we can look forward to his further progress in developing novel approaches for new treatments."
Additional information about the Lupus Insight Prize and Dr. Shlomchik's work in lupus are available online at www.lupusinsightprize.org. Information on the application process for the 2014 Prize will be posted in the coming weeks.